Potential for Therapeutic Alteration of the Underlying Biology of Epilepsy
Abstract Approximately 30–35% of people with epilepsy experience seizures despite taking antiseizure medications. Recurrent seizures that are independent of status…
antiseizure medication
Analysis of six CYP450 genetic variants regarding the response to cannabidiol combined with anticonvulsant medication in mexican patients with drug-resistant epilepsy
Abstract Background: Cannabidiol (CBD) reduces the frequency of seizures in individuals with specific epileptic syndromes, but its effectiveness for other…
Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant focal epilepsies treated in the Expanded Access Program
Abstract Objective: Cannabidiol (CBD) treatment was associated with long‐term seizure reduction in patients with various treatment‐resistant epilepsies who participated in…
Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program
Abstract Objective: The cannabidiol (CBD) Expanded Access Program provided compassionate access to CBD for patients with treatment‐resistant epilepsy, including tuberous…
CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy
Abstract CDKL5 deficiency disorder (CDD) is a complex clinical condition resulting from non-functional or absent CDKL5 protein, a serine–threonine kinase…
Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies
Abstract Developmental and epileptic encephalopathies (DEEs) are rare neurodevelopmental disorders characterised by early-onset and often intractable seizures and developmental delay/regression,…
Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
Abstract Objective: To estimate the timing of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]) onset, we conducted…
Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial
Abstract Objective: To evaluate the long‐term safety and efficacy of add‐on cannabidiol (CBD) in patients with seizures associated with tuberous…
Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe
Abstract Dravet syndrome (DS) is a severe, rare, and complex developmental and epileptic encephalopathy affecting 1 in 16 000 live…
Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
Abstract Objective: To estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted…